Search PubMed⌕ Search

Biomedical subjects

V Wright

Publications and source records attributed to V Wright.

At least 181 records · Page 10Linked to original sources
PubMed1983

Captopril.

Explore the source record for details and available documents.

Arthritis, Rheumatoid↗
PubMed1983

Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

Sulphasalazine was first formulated by Svartz in the early 1940s, specifically for use as a remission inducing drug in rheumatoid arthritis. After the publication of an unfavourable trial, however, the drug was restricted to patients with ulcerative colitis. In the late 1970s sulphasalazine was re-examined in rheumatoid arthritis and favourable results reported in "open" trials. A double blind controlled trial was therefore conducted comparing enteric coated sulphasalazine and D-penicillamine in patients with active rheumatoid arthritis. A total of 63 patients were recruited in two centres; 31 were treated with sulphasalazine and 32 received penicillamine. After 16 weeks' treatment both drugs had produced significant improvements in clinical score, pain score measured on a visual analogue scale, grip strength, Ritchie articular index, erythrocyte sedimentation rate, and serum C reactive protein concentration. Nausea was the major side effect in the sulphasalazine treated group. No potentially dangerous effects of sulphasalazine were encountered in contrast with those seen in the penicillamine group. The results suggest that sulphasalazine is an effective and safe drug capable of producing remissions in active rheumatoid arthritis. They also lend confidence to the use of preliminary "open" trials as a means of screening for remission inducing drugs in rheumatoid arthritis.

Adult↗
PubMed1983

A phenylbutazone dose-finding study in rheumatoid arthritis.

Different doses of phenylbutazone have been compared in a double blind study on 32 patients with rheumatoid arthritis in order to determine the minimum effective dose. Of 8 different dose levels studied (90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg and 450 mg/day) the most efficacious was found to be 300 mg/day. Doses below this did not produce full benefit; no further improvement occurs with higher doses. Although 7/32 patients developed adverse reactions there was no relationship between these and the plasma levels of either phenylbutazone or oxyphenbutazone. An attempt was made to distinguish 'responders' from 'non-responders'. We found no relationship between response and plasma levels of phenylbutazone or oxyphenbutazone.

Adult↗
PubMed1983

Serum biochemistry in relation to the action of azathioprine in rheumatoid arthritis.

In a long-term study we have been comparing biochemical changes in the blood of patients with classical or definite rheumatoid arthritis (RA) when groups of patients are treated for the first time with specific anti-rheumatoid drugs for a six-month period. One such group was treated for 26 weeks with azathioprine. Biochemical and clinical assessments were made at each of 10 clinic visits during the treatment period. Side-effects prevented six patients completing the study. Clinical improvement in the remaining patients was accompanied by a reduction in acute phase proteins, increases in total serum sulphydryl and serum histidine, but little or no change in immunological variables. Comparison of correlation matrices constructed between clinical and laboratory variables for azathioprine and drugs previously tested suggests that azathioprine is more effective than a control group on aspirin alone and in some ways comparable with D-penicillamine.

Aged↗
PubMed1983

A comparison of platelet count and acute phase proteins in the measurement of disease activity in rheumatoid arthritis.

Platelet count (PC) was compared with standard acute phase reactants (ESR, plasma viscosity and C-reactive protein) and clinical measurements to assess its usefulness as a measure of disease activity in 165 patients with active rheumatoid arthritis. Although PC was elevated (greater than 400 X 10(9) 1(-1) in 45% of patients and was seen to fall under the influence of second-line drugs, it was considered to be unsuitable as an indication of disease activity since levels fall for reasons other than disease improvement.

Anti-Inflammatory Agents↗
PubMed1983

Pathogenesis of seronegative arthritis.

The concept of seronegative spondarthritis, linking several diseases around ankylosing spondylitis, has received considerable clinical and genetic support, especially through the discovery of a high frequency of HLA-B27 in these disorders. Exogenous factors would appear to be responsible for some manifestations of the disease, but the role of Klebsiella micro-organisms is equivocal, and dietary control does not affect clinical manifestations. Increased serum and salivary IgA antibodies in active ankylosing spondylitis patients tend to suggest that IgA may act as an acute-phase reactant.

HLA Antigens↗
PubMed1983

Factors that may influence the prescribing habits of rheumatologists.

Questionnaire replies were received from 86% of all members of the British Association for Rheumatology and Rehabilitation soliciting opinions regarding influences and attitudes to prescribing. The importance and quality of information sources for new drugs were assessed and the importance of various aspects of information considered to be necessary for inclusion in a data card were investigated. The results indicated the professional journals and independent sources such as the Prescribers Journal are highly thought of by Rheumatologists and that advertisements and 'popular' journals are less likely to be important in the transmission of awareness of a new drug. The most important aspects of information considered to be necessary for inclusion in a data card or information bulletin were adverse- or side-effects. Specific details of the drug formulation or presentation are considered to be of much less importance. Rheumatologists prefer to prescribe by generic name and are likely to use two or three drugs in the treatment of a patient.

Drug Prescriptions↗
PubMed1983

Crohn's spondylitis: a family study.

We report a case of HLA B27 negative Crohn's spondylitis with a detailed study of the proband's family, including tissue types of all living relatives. The family included cases of psoriasis, psoriatic spondylitis, and idiopathic ankylosing spondylitis. We believe this to be the first report of these associated diseases occurring in one family. All relatives were B27 negative, including one with psoriatic spondylitis. The aetiological implications of these findings are considered.

Crohn Disease↗
PubMed1983

Gastro-intestinal blood loss with high dose tilcotil (Ro 12-0068) and aspirin: an open crossover clinical trial and pharmacokinetic assessment in normal volunteers.

An open crossover study was carried out in 8 normal volunteer subjects to compare faecal blood loss resulting from tilcotil (Ro12-0068), a new anti-inflammatory agent, and from enteric-coated aspirin. After a 1-week run-in period, subjects were allocated at random to receive treatment for 2 weeks with either 40 mg tilcotil as a single dose per day or aspirin, 900 mg 4-times daily, reduced if necessary to a maximum tolerated dose. Subjects were then crossed over to the alternative treatment for a further 2 weeks. The results showed that tilcotil produced less blood loss, assessed by a radioactive labelling method, and was better tolerated than aspirin. Plasma concentrations of tilcotil showed that the drug's half-life was approximately 50 hours, compatible with once daily dosage, and steady state concentrations on multiple dosing were reached after 10 to 12 days.

Adult↗